Free Trial

Molecular Templates (MTEM) Insider Trading & Ownership

Molecular Templates logo
$0.46
+0.01 (+2.23%)
(As of 11/1/2024 ET)

Molecular Templates (NASDAQ:MTEM) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
13.60%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$587,500.00
Number Of
Insiders Selling
(Last 12 Months)
0
Get MTEM Insider Trade Alerts

Want to know when executives and insiders are buying or selling Molecular Templates stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

MTEM Insider Buying and Selling by Quarter

Molecular Templates Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/2/2024Target N V BiotechMajor ShareholderBuy250,000$2.35$587,500.00  
(Data available from 1/1/2013 forward)

MTEM Insider Trading Activity - Frequently Asked Questions

The list of insiders at Molecular Templates includes Kevin M Lalande, Sean Mclennan, Shv Management Services, Llc, and Target N V Biotech. Learn more on insiders at MTEM.

13.60% of Molecular Templates stock is owned by insiders. Learn more on MTEM's insider holdings.

The following insider purchased MTEM shares in the last 24 months: Target N V Biotech ($2,587,493.35).

Insiders have purchased a total of 533,687 MTEM shares in the last 24 months for a total of $2,587,493.35 bought.

Molecular Templates Key Executives

  • Dr. Eric E. Poma Ph.D. (Age 52)
    CEO, Chief Scientific Officer & Director
    Compensation: $723.81k
  • Ms. Jason S KimMs. Jason S Kim (Age 49)
    President, CFO, Treasurer & Principal Accounting Officer
    Compensation: $522.3k
  • Ms. Kristen Quigley B.A. (Age 53)
    Chief Operating Officer
  • Dr. Grace Kim
    Chief Strategy Officer & Head of IR
  • Dr. Michelle Iwamoto-Fan J.D.
    Ph.D., Senior Vice President & General Counsel
  • Dr. Joseph Phillips Ph.D.
    Senior VP & Head of CMC Development
  • Dr. Chris Moore Ph.D.
    Senior VP and Head of Preclinical Development & Translational Medicine


This page (NASDAQ:MTEM) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners